Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Vinylphenol SCHEMBL28409703 | 0.83 | DPYD (0.69) | DPYDMAPTGAAALDH1A1LMNA | |
| SCHEMBL48228 | 0.79 | DPYD (0.65) | DPYDMAPTGAAALDH1A1LMNA | |
| SCHEMBL1916591 | 0.77 | DPYD (0.63) | DPYDMAPTGAAALDH1A1LMNA | |
| SCHEMBL28624115 | 0.77 | DPYD (0.62) | DPYDMAPTGAAALDH1A1LMNA | |
| SCHEMBL6374582 | 0.74 | DPYD (0.59) | DPYDMAPTGAAALDH1A1LMNA | |
| SCHEMBL15798473 | 0.74 | DPYD (0.62) | DPYDMAPTGAAALDH1A1LMNA | |
| SCHEMBL6374591 | 0.74 | DPYD (0.59) | DPYDMAPTGAAALDH1A1LMNA | |
| SCHEMBL65892 | 0.74 | DPYD (0.62) | DPYDMAPTGAAALDH1A1LMNA | |
| SCHEMBL933037 | 0.74 | DPYD (0.59) | DPYDMAPTGAAALDH1A1LMNA | |
| SCHEMBL190377 | 0.74 | DPYD (0.59) | DPYDMAPTGAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 578 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20240117431-A1 | STEM-CELL BASED BIOMARKER DISCOVERY | UNIV CALIFORNIA (US) | 2024-04-11 | — | — | US | claimed |
| CN-111268842-B | Sewage treatment method | 濮阳市盛源能源科技股份有限公司 | 2022-05-20 | — | — | CN | claimed |
| CN-111303612-B | Blue-light-proof polyurethane optical resin material | 万华化学集团股份有限公司 | 2022-02-15 | — | — | CN | claimed |
| CN-111268842-A | Sewage treatment method | 濮阳市盛源能源科技股份有限公司 | 2020-06-12 | — | — | CN | claimed |
| US-9822326-B2 | Low viscosity, low volatility lubricating oil basestocks | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2017-11-21 | — | — | US | claimed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| EP-0726904-A1 | 5-FLUOROURACIL DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | claimed |
| EP-0494370-B1 | Antiviral (phosphonomethoxy)methoxy purine/pyrimidine derivatives | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1995-06-28 | — | — | EP | claimed |
| WO-1995012606-A1 | 5-FLUOROURACIL DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-05-11 | — | — | WO | claimed |
| US-5386030-A | Chemical intermediates | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCE OF THE CZECH REPUBLIC (CZ) | 1995-01-31 | — | — | US | claimed |
| EP-0630381-A4 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | — | 1995-01-04 | — | — | EP | claimed |
| EP-0630381-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1994-12-28 | — | — | EP | claimed |
| US-5208221-A | Nucleotides and intermediates for herpes virus or leukemia virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-05-04 | — | — | US | claimed |
| WO-1993007157-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OFTHE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1993-04-15 | — | — | WO | claimed |
| US-5126506-A | Deoxygenation at 3-position of furan ring | BRISTOL-MYERS COMPANY (US) | 1992-06-30 | — | — | US | claimed |
| EP-0269947-A1 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1988-06-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | DPYD 369/4885MAPT 3589/4885GAA 554/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | DPYD 369/4885MAPT 3589/4885GAA 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.